CRDL Cardiol Therapeutics Inc.
Cardiol Therapeutics Inc. (CRDL) is expected to report earnings on November 11, 2026, before the market open. The consensus earnings estimate is a loss of $0.08 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +19.2% since its last earnings release on August 12, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Cardiol Therapeutics Inc.
Cardiol Therapeutics Inc. is a clinical-stage biotechnology company. It focused on developing innovative anti-inflammatory therapies for the treatment of cardiovascular disease. The company's lead product consist CardiolRx(TM). Cardiol Therapeutics Inc. is based in Oakville, ON.
Sector
Healthcare
Industry
Drug Manufacturers/Other